IDWEEK 2016 – Vaccines


GSK’s investigational combined measles, mumps, and rubella (MMR) vaccine (GSK_MMR) “demonstrated an acceptable immune response” that was non-inferior to Merck’s MMR vaccine (MRK_MMR), a multinational, randomized, Phase 3A, controlled, observer-blinded study reported at IDWeek 2016 has shown.

Population level-analyses between 2003-2013 found no links between sudden infant death syndrome (SIDS), attention-deficit/hyperactivity disorder (ADHD), and vaccines, Jana Shaw, MD, MPH, Associate Professor of Pediatrics, Pediatric Infectious Diseases, Upstate Golisano Children’s Hospital, State University of New York, Syracuse, NY, presented at IDWeek 2016.